Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy
Completed · Phase 2
Conditions studied: Lymphoma, B-Cell
In brief
Purpose of Phase II study for B-cell lymphoma using PS341: Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Key facts
- Study ID
- NCT00038571
- Run by
- M.D. Anderson Cancer Center
- People needed
- 60
- Starts
- 2002-05-01
- Expected to finish
- 2005-03-01
- Last updated by the study team
- 2018-10-31
Who can join
Age: 17 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UT MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.